ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, today announced the oral presentation of “Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients (Cohort A)” during a session at the Genitourinary Cancers Symposium sponsored by the American Society of Clinical Oncology (ASCO). The data showed 51 out of 72 evaluable patients (71%), with 10
